Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Current Assets (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Current Assets for 6 consecutive years, with $975.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 5.59% to $975.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $975.9 million, a 5.59% decrease, with the full-year FY2025 number at $975.9 million, down 5.59% from a year prior.
  • Current Assets was $975.9 million for Q4 2025 at Janux Therapeutics, down from $998.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.0 billion in Q4 2024 to a low of $309.3 million in Q2 2023.
  • A 5-year average of $574.8 million and a median of $389.6 million in 2021 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: surged 2247.27% in 2021, then fell 13.62% in 2023.
  • Janux Therapeutics' Current Assets stood at $377.0 million in 2021, then fell by 11.82% to $332.4 million in 2022, then grew by 5.05% to $349.2 million in 2023, then surged by 195.97% to $1.0 billion in 2024, then fell by 5.59% to $975.9 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Current Assets are $975.9 million (Q4 2025), $998.1 million (Q3 2025), and $1.0 billion (Q2 2025).